Enovis (NYSE:ENOV) Stock: Insider Sharon Wienbar Buys 874 Shares

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar purchased 874 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was bought at an average price of $28.43 per share, with a total value of $24,847.82. Following the purchase, the director owned 44,651 shares of the company’s stock, valued at approximately $1,269,427.93. The trade was a 2.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Enovis Stock Up 0.4%

ENOV traded up $0.10 during trading on Friday, hitting $27.74. The company had a trading volume of 1,205,392 shares, compared to its average volume of 1,879,055. The company has a market cap of $1.60 billion, a PE ratio of -3.01 and a beta of 1.31. The business has a 50-day moving average of $20.52 and a 200-day moving average of $23.22. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08. Enovis Corporation has a 1-year low of $16.70 and a 1-year high of $31.67.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The firm had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm’s revenue was up 1.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 EPS. As a group, analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several research analyst reports. BMO Capital Markets set a $27.00 price target on shares of Enovis in a research report on Tuesday, September 1st. Wells Fargo & Company boosted their price objective on Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Needham & Company LLC upped their price objective on Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. UBS Group reaffirmed a “buy” rating and set a $44.00 target price on shares of Enovis in a report on Monday, October 5th. Finally, Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and an average target price of $38.62.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Allworth Financial LP lifted its holdings in Enovis by 59.7% in the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after acquiring an additional 652 shares during the last quarter. IFP Advisors Inc boosted its stake in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares during the period. Inspire Investing LLC boosted its stake in Enovis by 4.9% in the third quarter. Inspire Investing LLC now owns 34,833 shares of the company’s stock valued at $636,000 after acquiring an additional 1,631 shares during the period. Amundi grew its holdings in shares of Enovis by 2.3% during the first quarter. Amundi now owns 74,184 shares of the company’s stock valued at $1,688,000 after purchasing an additional 1,677 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Enovis by 9.3% during the second quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock valued at $437,000 after purchasing an additional 1,800 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis News Roundup

These are some of the ENOV news items that stood out recently:

• Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.